Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laura Lema
Observed name:
L. Lema
Institutions:
Research Institute Hospital 12 de Octubre,
Hospital Universitario 12 De Octubre
Observed institutions:
Research Institute Hospital 12 de Octubre,
Institut d'Investigació Biomédica de Bellvitge,
Hospital Universitario 12 De Octubre,
Institut Català d'Oncologia
ORCID:
0000-0001-8527-3398
Observed ORCID:
0000-0001-8527-3398
OpenAlex ID:
A5103980458
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort
2024
·
Rodrigo Sánchez-Bayona
, Alfonso Lopez de Sa
, et al.
·
Breast Cancer Research and Treatment
·
27
Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer
2015
·
Margarita García
, Mercedes Martinez-Villacampa
, et al.
·
BMC Cancer
·
23
PDF
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab
2025
·
Rodrigo Sánchez-Bayona
, Olga Martínez-Sáez
, et al.
·
npj Breast Cancer
·
14
PDF
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study
2025
·
Pablo Tolosa
, Tomás Pascual
, et al.
·
European Journal of Cancer
·
12
Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
2023
·
Santiago Terán
, Manuel Alva
, et al.
·
The Breast
·
6
PDF
Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies
2024
·
Ainhoa Madariaga
, Rodrigo Sánchez-Bayona
, et al.
·
International Journal of Gynecological Cancer
·
5
Abstract P5-13-24: Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancer
2022
·
Rodrigo Sanchez-Bayona
, Santiago Terán
, et al.
·
Cancer Research
·
5
Abstract PO-020: Impact of CDK 4/6i withdrawal or dose adjustment on COVID-19 incidence in HR+/HER2- mBC patients during the pandemic
2020
·
Pablo Tolosa
, Ana Sanchez-Torre
, et al.
·
Clinical Cancer Research
·
4
Abstract RF5-05: Predicting olaparib sensitivity in patients with metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations according to their homologous recombination status by the RAD51 test: Primary analysis of the RADIOLA phase II trial
2026
·
I. Pimentel
, T. Pascual
, et al.
·
Clinical Cancer Research
·
3
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study
2025
·
Manuel Ruiz Borrego
, David Páez López-Bravo
, et al.
·
European Journal of Cancer
·
2
Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation
2025
·
Laura Lema
, José Manuel Pérez-García
, et al.
·
Cancers
·
2
PDF
Development of a multiparametric prognostic score based on PAM50, in patients with HR+/HER2- advanced breast cancer (aBC) treated with endocrine therapy (ET) plus cyclin dependent kinase 4 and 6 inhibitors (CDKi), within the CDK-PREDICT (SOLTI-1801) study and HCB cohort.
2024
·
Pablo Tolosa Ortega
, Tomás Pascual
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer
2026
·
M. Cruellas
, A. Rodriguez-Hernandez
, et al.
·
ESMO Open
·
1
PDF
Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer
2026
·
Lola R. Nogueira
, Ana Maderuelo
, et al.
·
International Journal of Molecular Sciences
·
1
PDF
Abstract PS2-09-26: Circulating microRNA and cytokine signatures associated with interstitial lung disease in patients treated with trastuzumab deruxtecan
2026
·
M. Alva Bianchi
, M. Cobos
, et al.
·
Clinical Cancer Research
·
1
Abstract P3-09-22: Phenomenal: Efficacy and safety of liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases
2025
·
Manuel Ruiz Borrego
, David Páez López-Bravo
, et al.
·
Clinical Cancer Research
·
1
Automated conversational artificial intelligence (AI) for outpatient malignant bowel obstruction (MBO) symptom monitoring.
2025
·
Ainhoa Madariaga
, Isabel Tuñon
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Proactive assessment of patient reported outcomes in patients with ovarian cancer.
2023
·
Ainhoa Madariaga
, Rodrigo Sanchez-Bayona
, et al.
·
Journal of Clinical Oncology
·
1
Abstract P3-01-04: A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2- advanced breast cancer
2023
·
Rodrigo Sánchez-Bayona
, Manuel Alva
, et al.
·
Cancer Research
·
1
Abstract OT2-19-03: Solti-1801. Analysis of the efficacy of CDK4/6 inhibitors in combination with hormonal treatment in luminal breast cancer in relation to the intrinsic subtype and markers of immunity (CDK-predict)
2022
·
Pablo Tolosa
, Tomás Pascual
, et al.
·
Cancer Research
·
1
Abstract OT-26-04: Solti-1801. Analysis of the efficacy of CDK4/6 inhibitors in combination with hormonal treatment in luminal breast cancer in relation to the intrinsic subtype and markers of immunity (CDK-PREDICT)
2021
·
Pablo Tolosa
, Tomás Pascual
, et al.
·
Cancer Research
·
1
Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors
2026
·
Santiago Terán
, María Illia
, et al.
·
Breast Cancer Research and Treatment
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study
2026
·
Pablo Tolosa
, Isabel García-Fructuoso
, et al.
·
Breast Cancer Research and Treatment
PDF
Abstract PS4-07-06: Independent validation of TNBCDX, a 15-gene genomic risk stratification tool for early-stage triple-negative breast cancer
2026
·
F. Braso-Maristany
, E. Ciruelos
, et al.
·
Clinical Cancer Research
EE418 Estimating Costs Avoided by Preventing Recurrences With a BRCA Testing Strategy in High-Risk HER2-Negative Adjuvant Breast Cancer Patients in Spain
2025
·
Ana M. Santaballa
, Laura Lema
, et al.
·
Value in Health
Show more works
View as search
Works count:
34
Citation count:
114
H-index:
5
I10-index:
4
Year
Topic
Type